Trinity Biotech (TRIB) investor relations material

Company overview and business model

• Commercial-stage biotechnology company focused on diabetes management and human diagnostics, including wearable biosensors.

• Develops, acquires, manufactures, and markets diagnostic systems for point-of-care and clinical laboratory segments.

• Product portfolio includes systems for detecting infectious diseases and quantifying Haemoglobin A1c and other chemistry parameters.

• Plans to expand biosensor devices and services, starting with a continuous glucose monitoring (CGM) product.

Financial performance and metrics

• As of December 31, 2025, total indebtedness was approximately $134.58 million, including principal and accrued interest under various credit agreements and convertible notes.

• Senior secured term loan outstanding was $100.82 million, repayable in January 2027.

• Cash and cash equivalents as of September 30, 2025, were $1.34 million (actual) and $8.34 million (as adjusted).

• Shareholders' equity as of September 30, 2025, was $50.27 million (actual) and $61.50 million (as adjusted).

Use of proceeds and capital allocation

• May receive up to $25 million in gross proceeds from the sale of ADSs to the Selling Securityholder under the Purchase Agreement.

• Proceeds intended for operating expenses, working capital, strategic, and general corporate purposes.

• Management has broad discretion over the specific use of net proceeds.